Eupraxia Pharmaceuticals Files 6-K, Includes Press Release
Ticker: EPRX · Form: 6-K · Filed: Sep 4, 2024 · CIK: 1581178
Sentiment: neutral
Topics: reporting, foreign-private-issuer, press-release
TL;DR
Eupraxia Pharma filed a 6-K on Sept 4, includes press release, will file 40-F.
AI Summary
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on September 4, 2024, reporting as a foreign private issuer. The filing indicates that the company will file annual reports under Form 40-F, not Form 20-F. Exhibit 99.1, a press release dated September 4, 2024, is included as part of this report.
Why It Matters
This filing provides an update on Eupraxia Pharmaceuticals' reporting status and includes a press release, which may contain material information for investors.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily serves to include a press release and confirm reporting status, with no immediate indication of significant financial or operational changes.
Key Players & Entities
- Eupraxia Pharmaceuticals Inc. (company) — Registrant
- September 4, 2024 (date) — Filing date and press release date
- Form 6-K (document) — Filing type
- Form 40-F (document) — Annual report filing type
- Exhibit 99.1 (document) — Included exhibit
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report as a foreign private issuer and to include Exhibit 99.1, a press release dated September 4, 2024.
Which form will Eupraxia Pharmaceuticals Inc. use for its annual reports?
Eupraxia Pharmaceuticals Inc. will file its annual reports under cover of Form 40-F.
What is the filing date of this report?
This report was filed on September 4, 2024.
What is the principal executive office address of Eupraxia Pharmaceuticals Inc.?
The principal executive office address is 201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada V8R 5G4.
What is the telephone number listed for Eupraxia Pharmaceuticals Inc.?
The telephone number listed is (250) 590-3968.
Filing Stats: 169 words · 1 min read · ~1 pages · Grade level 14.6 · Accepted 2024-09-04 07:01:34
Filing Documents
- form6k.htm (6-K) — 11KB
- ex991.htm (EX-99.1) — 13KB
- logo.jpg (GRAPHIC) — 23KB
- 0001279569-24-001075.txt ( ) — 57KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Eupraxia Pharmaceuticals Inc. Date: September 4, 2024 By: /s/ Bruce Cousins Name: Bruce Cousins Title: President and Chief Financial Officer